Routine measurement of FFR during PCI reduced the composite endpoint of death, nonfatal myocardial infarction, and repeat revascularization at 1 year.
Does routine measurement of FFR reduce the composite end point of death, nonfatal myocardial infarction, and repeat revascularization in patients with multivessel coronary artery disease undergoing PCI with drug-eluting stents?
Routine FFR guidance during PCI for multivessel coronary artery disease significantly improves 1-year clinical outcomes compared to angiography guidance alone.
Absolute Event Rate: 0% vs 0%
Routine measurement of FFR in patients with multivessel coronary artery disease who are undergoing PCI with drug-eluting stents significantly reduces the rate of the composite end point of death, nonfatal myocardial infarction, and repeat revascularization at 1 year. (ClinicalTrials.gov number, NCT00267774.)
Tonino et al. (Wed,) reported a other. Routine measurement of FFR during PCI reduced the composite endpoint of death, nonfatal myocardial infarction, and repeat revascularization at 1 year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: